Company intelligence / Profile preview
Calmmax Pharma
Suzhou, Jiangsu, Chinacalmmaxpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Calmmax Pharma is a clinical-stage biopharmaceutical company headquartered in China, specializing in the development of small molecule drugs for inflammatory, respiratory, and metabolic disorders. The company focuses on targeting G protein-coupled receptors (GPCRs) and ion channels to create first-in-class or best-in-class therapies. Its lead candidate, CM001, is a GPR84 antagonist currently being evaluated for idiopathic pulmonary fibrosis and NASH. Additionally, the company is advancing CM002, a P2X3 antagonist, for the treatment of refractory chronic cough. Calmmax is supported by prominent venture capital firms and maintains research facilities in Suzhou and Shanghai.
- Therapeutic areas
- PulmonologyGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Calmmax Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Calmmax Pharma.